May 15, 2007 — /PRNewswire-FirstCall/ — PASADENA, CA — Jacobs Engineering Group Inc. announced today that it received a contract from Biogen Idec to provide engineering, procurement, validation, and site support services for the first cell culture manufacturing facility at the greenfield biotechnology plant in Hillerod, Denmark. The manufacturing facility is expected to produce TYSABRI(R) (natalizumab), which is used in the treatment of multiple sclerosis.
Officials did not disclose the contract details but noted that the plant is scheduled to be completed in 2009.
Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. The company creates new standards of care in therapeutic areas with high unmet medical needs and has significant products serving patients in more than 90 countries. This will be its first manufacturing facility in Europe. Jacobs performed conceptual design for the facility and will execute this new scope of work from its office in Reading, England.
In making the announcement, Jacobs Group vice president Phil Stassi said, “We are very enthusiastic about continuing our collaboration with Biogen Idec to help them bring this important drug treatment to market. This award strengthens our position as the leading engineering contractor for large European biotech projects.”
Jacobs, with over 46,000 employees and revenues exceeding $8.0 billion, provides technical, professional, and construction services globally.
Mary Bloom, Jacobs Engineering Group
Web site: http://www.jacobs.com/